alpha-synucleine A53T humain, recombinant, exprimé en E. coli, N-terminal histidine étiqueté, >=90% (SDS - PAGE) , poudre lyophilisée

Code: s1071-500ug D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

α-Synuclein A53T human has been used to treat mesencephalic neuronal and stimulate microglial cells prior to reactive oxygen species (ROS) measurement, immunohist...


en savoir plus

Votre prix
£569.00 500UG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

α-Synuclein A53T human has been used to treat mesencephalic neuronal and stimulate microglial cells prior to reactive oxygen species (ROS) measurement, immunohistochemistry and imaging studies.

Biochem/physiol Actions

A point mutation in the α-synuclein gene, A53T (Ala53-Thr), is linked to familial Parkinson′s disease. Mice expressing A53T human α-synuclein, but not wild-type or the A30P variants, develop adult-onset neurodegenerative disease with a progressive motoric dysfunction leading to death.

α-Synuclein (α-Syn) interacts with toll-like receptor 2 (TLR2) and mediates interleukin-1β (IL-1β) synthesis.

General description

α-Synuclein is mapped to human chromosome 4q22.1. It is an intrinsically disordered protein with N-terminal imperfect repeats (KTKEGV), a central NAC crucial for aggregation and an acidic rich flexible C-terminal region.α-Synuclein is present in the Lewy bodies (LBs) and Lewy neurites (LNs).

assay≥90% (SDS-PAGE)
formlyophilized powder
Gene Informationhuman ... SNCA(6622)
Quality Level200
recombinantexpressed in E. coli
shipped indry ice
storage temp.−20°C
UniProt accession no.P37840
Ce produit répond aux critères suivants: